Zentalis(ZNTL) - 2024 Q2 - Quarterly Results

Exhibit 99.1 Zentalis Pharmaceuticals Reports Second Quarter 2024 Financial Results and Operational Progress $426.4M cash, cash equivalents and marketable securities as of June 30, 2024; Projected cash runway into mid-2026 SAN DIEGO — August 9, 2024 — Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways of cancers, today announced financial results ...